Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Researchers Send Cancer-fighting Drugs to Lungs

By Drug Discovery Trends Editor | June 29, 2011

Researchers from the Hamner Institutes for Health Sciences,with support from the National Cancer Institute, have shown that administering cancer-preventive drugs directly to target lung tissue via aspiration is an effective and inexpensive alternative to the traditional inhalation method.

In a study, scientists demonstrated that Licofelone, a novel analgesic and anti-inflammatory agent, was successful in low doses at inhibiting tumor progression in a human surrogate lung cancer model. The study is the first of its kind to show that aspiration is an effective alternative for direct delivery of chemopreventive drugs to the lungs.

The  researchers tested the efficacy of nontoxic doses of Licofelone against Benzo[a]pyrene – a key cancer-causing chemical found in tobacco smoke–induced tumors in a human surrogate lung cancer model by a 16-week exposure. In addition to confirming efficacy in treating tumor growth, Licofelone was also shown to have a high correlation to early and late biomarkers of lung cancer progression. Licofelone, a possible breakthrough treatment for osteoarthritis that is currently undergoing Phase III clinical trials, has also been shown to be effective against a series of other cancers, including pancreatic cancer.

The results of this study indicate that the aspiration route could be highly useful for assessing potential anticancer drug candidates in the current human surrogate lung tumor model mimicking former or current smokers.

“The aspiration route has direct applicability in humans, as the drug will be delivered by the use of an oral metered inhaler, which uses the same route as the aspiration,” says Sheela Sharma, MD, director of The Hamner Center for preclinical safety and efficacy. “This method of administration would further reduce the toxicity of the drug – and thus the potential for side effects – as well as increase the overall efficacy of the treatment.”

The findings were published online in Cancer Prevention Research.

Release Date: June 23, 2011
Source: The Hamner Institutes for Health Sciences 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE